Research ArticleClinical Studies

RBM17 Expression Is Associated With the Efficacy of ICI Monotherapy in NSCLC With Low PD-L1 Expression

HIROAKI NAGAMINE, MASAKAZU YASHIRO, NAOKI YOSHIMOTO, MOTOHIRO IZUMI, AKIRA SUGIMOTO, KENJI NAKAHAMA, KOICHI OGAWA, YOSHIYA MATSUMOTO, KENJI SAWA, YOKO TANI, HIROYASU KANEDA, SHIGEKI MITSUOKA, KAZUHIRO YAMADA, TETSUYA WATANABE, KAZUHISA AASAI, KAZUHIRO FUKUMURA, AKILA MAYEDA and TOMOYA KAWAGUCHI
Anticancer Research October 2023, 43 (10) 4663-4672; DOI: https://doi.org/10.21873/anticanres.16662

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.

patientACCESS

patientACCESS - Patients desiring access to articles
Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools
Reprints and Permissions
RBM17 Expression Is Associated With the Efficacy of ICI Monotherapy in NSCLC With Low PD-L1 Expression
HIROAKI NAGAMINE, MASAKAZU YASHIRO, NAOKI YOSHIMOTO, MOTOHIRO IZUMI, AKIRA SUGIMOTO, KENJI NAKAHAMA, KOICHI OGAWA, YOSHIYA MATSUMOTO, KENJI SAWA, YOKO TANI, HIROYASU KANEDA, SHIGEKI MITSUOKA, KAZUHIRO YAMADA, TETSUYA WATANABE, KAZUHISA AASAI, KAZUHIRO FUKUMURA, AKILA MAYEDA, TOMOYA KAWAGUCHI
Anticancer Research Oct 2023, 43 (10) 4663-4672; DOI: 10.21873/anticanres.16662
Twitter logo Facebook logo Mendeley logo

Jump to section

Keywords